In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.
(RTTNews) - IO Biotech (IOBT) announced that the Independent Data Monitoring Committee found the data from the Pivotal Phase 3 Trial of IO102-IO103 in combination with KEYTRUDA (pembrolizumab ...
The vials should be easier to manufacture than ... evaluating blockbuster PD-L1 inhibitor Keytruda for a type of lung cancer and skin cancer, respectively. The studies were stopped on the ...
Eli Lilly LLY launched a discounted single-dose vial version of its popular obesity ... evaluating blockbuster PD-L1 inhibitor Keytruda for a type of lung cancer and skin cancer, respectively.
Eli Lilly LLY launched a discounted single-dose vial version of its popular obesity drug ... evaluating blockbuster PD-L1 inhibitor Keytruda for a type of lung cancer and skin cancer, respectively.
London: Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday, marking the latest set of trial ...
Merck said Thursday morning it is discontinuing two Phase 3 trials of Keytruda, the world’s top-selling medicine, after independent data monitoring … ...
Merck is discontinuing the Phase 3 KEYNOTE-867 trial evaluating Keytruda (pembrolizumab) in combination with stereotactic body radiotherapy (SBRT) for stage I or II non-small cell lung cancer ...
A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.
NEW YORK – Merck on Thursday said it is discontinuing the Phase III KEYNOTE-630 trial of Keytruda (pembrolizumab) as adjuvant therapy in patients with high-risk, locally advanced cutaneous squamous ...